Skip to main content
Fig. 1 | Cell Communication and Signaling

Fig. 1

From: Targeted Silencing of NRF2 by rituximab-conjugated nanoparticles increases the sensitivity of chronic lymphoblastic leukemia cells to Cyclophosphamide

Fig. 1

RTX-CL-NPs loaded with CP and anti-Nrf2 siRNA (NP-Nrf2_siRNA-CPs) induced pathways within CLL malignant cells. As pictured here, RTX causes specific targeting of leukemic CD20 + cells by NP-Nrf2_siRNA-CPs which enhances cell entry efficacy. Subsequently, Acidic microenvironment of malignant cells causes CP and anti-Nrf2 siRNA release from NPs. Anti-Nrf2 siRNA interferes with Nrf2 mediated cellular pathways which lead to apoptosis induction, decreased drug resistance, and suppressed cellular proliferation. Furthermore, RTX promotes cell apoptosis (PCD) making malignant CLL cells to be more susceptible to CP

Back to article page

Cell Communication and Signaling

ISSN: 1478-811X